Navigation Links
VETORYL(R) (Trilostane) Receives FDA Approval
Date:12/15/2008

OVERLAND PARK, Kan., Dec. 15 /PRNewswire/ -- Dechra Veterinary Products LLC today announces that the company has received FDA approval to market VETORYL(R) Capsules.

VETORYL Capsules contain the drug trilostane, which has been demonstrated to be effective in the treatment of Cushing's syndrome in dogs. VETORYL will be indicated for use in pituitary-dependent hyperadrenocorticism, which comprises the majority of cases of Cushing's syndrome in dogs. Additionally, VETORYL has received designation status as a Minor Use Drug for treatment of hyperadrenocorticism caused by adrenal tumors -- the first drug to receive an approval for this indication and the first drug to receive a Minor Use designation in dogs.

Mike Eldred, President of U.S. Operations, says, "We are very excited to have approval to market this novel product in the U.S. Following its launch in January, veterinarians will be able to source the product through our network of distribution partners."

Dechra Veterinary Products LLC, located in Overland Park, Kansas, is the U.S. subsidiary of Dechra Pharmaceuticals PLC, a UK listed company focused on international animal healthcare markets. Dechra currently markets a range of specialized veterinary products in the U.S. For more information, please visit http://www.dechra-us.com or call 866-933-2472.


'/>"/>
SOURCE Dechra Veterinary Products LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... , ... August 18, 2017 ... ... Quick International, LLC (“Quick”), a highly specialized asset-light logistics provider of complex ... into a definitive agreement to purchase Unitrans International Corporation, a division of ...
(Date:8/18/2017)... ... 18, 2017 , ... As an industry leader, Eppendorf is ... will present the line of epMotion automated liquid handling system. This automated liquid ... everyday pipetting tasks. , Ideal for scientists and lab technicians with no or ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston ... east Texas, is launching a regional charity effort to provide publicity assistance and ... Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... The Golseth ... in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to provide ... , In early June of this year, Christina and her children returned from out ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., a ... , today announced that the company has provided an ... of North Carolina at Chapel Hill and to Qura ... to characterize and quantify HIV reservoir and viral expression ... intervention. The HIV Cure Center is a joint initiative ...
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
(Date:8/7/2017)... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ...  All comparisons, unless otherwise noted, are to the quarter ended ... Second Quarter 2017 Highlights include: Revenue ... 3.5% Total prescriptions dispensed of 220,000, compared ... 7.6% Gross profit per prescription dispensed ...
Breaking Medicine Technology: